Cargando…
Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area
BACKGROUND: In settings with low background prevalence of tuberculosis (TB) infection, interferon-γ release assays (IGRA) could be useful for diagnosing active TB. This study aims to evaluate the performance of QuantiFERON(®)-TB Gold (QFT-G) in the investigation for suspected active TB, with particu...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713243/ https://www.ncbi.nlm.nih.gov/pubmed/19575781 http://dx.doi.org/10.1186/1471-2334-9-105 |
_version_ | 1782169564535062528 |
---|---|
author | Winqvist, Niclas Björkman, Per Norén, Ann Miörner, Håkan |
author_facet | Winqvist, Niclas Björkman, Per Norén, Ann Miörner, Håkan |
author_sort | Winqvist, Niclas |
collection | PubMed |
description | BACKGROUND: In settings with low background prevalence of tuberculosis (TB) infection, interferon-γ release assays (IGRA) could be useful for diagnosing active TB. This study aims to evaluate the performance of QuantiFERON(®)-TB Gold (QFT-G) in the investigation for suspected active TB, with particular attention to patients originating in high-incidence countries. Furthermore, factors associated with QFT-G results in patients with active TB were assessed. METHODS: From patients investigated for clinically suspected active TB, blood was obtained for QFT-G testing, in addition to routine investigations. Positive (PPV) and negative (NPV) predictive values for QFT-G were calculated, comparing patients with confirmed TB and those with other final diagnoses. QFT-G results in TB patients originating from countries with intermediate or high TB incidence were compared with QFT-G results from a control group of recently arrived asymptomatic immigrants from high-incidence countries. Factors associated with QFT-G outcome in patients with confirmed TB were assessed. RESULTS: Among 141 patients, 41/70 (58.6%) with confirmed TB had a positive QFT-G test, compared to 16/71 (22.6%) patients with other final diagnoses, resulting in overall PPV of 71.9% and NPV of 67.6%. For patients with pulmonary disease, PPV and NPV were 61.1% and 67.7%, respectively, and 90.5% and 66.7% for subjects with extrapulmonary manifestations. Comparing patients from high-incidence countries with controls yielded a PPV for active TB of 76.7%, and a NPV of 82.7%. Patients with confirmed TB and positive QFT-G results were characterized by a lower median peripheral white blood cell count (5.9 × 10(9)/L vs. 8.8 × 10(9)/L; P < 0.001) and a higher median body mass index (22.7 vs. 20.7; P = 0.043) as compared to QFT-G-negative TB patients. CONCLUSION: The overall PPV and NPV of QFT-G for identifying active TB were unsatisfactory, especially for pulmonary disease. Thus, the usefulness of QFT-G for this purpose is questionable. However, a high PPV was observed for extrapulmonary TB and QFT-G might be considered in the diagnostic process in this situation. The PPV and NPV for identifying active TB among persons originating from regions with high-and intermediate TB incidence was similar to that observed in subjects originating in the low-incidence region. |
format | Text |
id | pubmed-2713243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27132432009-07-21 Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area Winqvist, Niclas Björkman, Per Norén, Ann Miörner, Håkan BMC Infect Dis Research Article BACKGROUND: In settings with low background prevalence of tuberculosis (TB) infection, interferon-γ release assays (IGRA) could be useful for diagnosing active TB. This study aims to evaluate the performance of QuantiFERON(®)-TB Gold (QFT-G) in the investigation for suspected active TB, with particular attention to patients originating in high-incidence countries. Furthermore, factors associated with QFT-G results in patients with active TB were assessed. METHODS: From patients investigated for clinically suspected active TB, blood was obtained for QFT-G testing, in addition to routine investigations. Positive (PPV) and negative (NPV) predictive values for QFT-G were calculated, comparing patients with confirmed TB and those with other final diagnoses. QFT-G results in TB patients originating from countries with intermediate or high TB incidence were compared with QFT-G results from a control group of recently arrived asymptomatic immigrants from high-incidence countries. Factors associated with QFT-G outcome in patients with confirmed TB were assessed. RESULTS: Among 141 patients, 41/70 (58.6%) with confirmed TB had a positive QFT-G test, compared to 16/71 (22.6%) patients with other final diagnoses, resulting in overall PPV of 71.9% and NPV of 67.6%. For patients with pulmonary disease, PPV and NPV were 61.1% and 67.7%, respectively, and 90.5% and 66.7% for subjects with extrapulmonary manifestations. Comparing patients from high-incidence countries with controls yielded a PPV for active TB of 76.7%, and a NPV of 82.7%. Patients with confirmed TB and positive QFT-G results were characterized by a lower median peripheral white blood cell count (5.9 × 10(9)/L vs. 8.8 × 10(9)/L; P < 0.001) and a higher median body mass index (22.7 vs. 20.7; P = 0.043) as compared to QFT-G-negative TB patients. CONCLUSION: The overall PPV and NPV of QFT-G for identifying active TB were unsatisfactory, especially for pulmonary disease. Thus, the usefulness of QFT-G for this purpose is questionable. However, a high PPV was observed for extrapulmonary TB and QFT-G might be considered in the diagnostic process in this situation. The PPV and NPV for identifying active TB among persons originating from regions with high-and intermediate TB incidence was similar to that observed in subjects originating in the low-incidence region. BioMed Central 2009-07-03 /pmc/articles/PMC2713243/ /pubmed/19575781 http://dx.doi.org/10.1186/1471-2334-9-105 Text en Copyright ©2009 Winqvist et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Winqvist, Niclas Björkman, Per Norén, Ann Miörner, Håkan Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area |
title | Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area |
title_full | Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area |
title_fullStr | Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area |
title_full_unstemmed | Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area |
title_short | Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area |
title_sort | use of a t cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713243/ https://www.ncbi.nlm.nih.gov/pubmed/19575781 http://dx.doi.org/10.1186/1471-2334-9-105 |
work_keys_str_mv | AT winqvistniclas useofatcellinterferongammareleaseassayintheinvestigationforsuspectedactivetuberculosisinalowprevalencearea AT bjorkmanper useofatcellinterferongammareleaseassayintheinvestigationforsuspectedactivetuberculosisinalowprevalencearea AT norenann useofatcellinterferongammareleaseassayintheinvestigationforsuspectedactivetuberculosisinalowprevalencearea AT miornerhakan useofatcellinterferongammareleaseassayintheinvestigationforsuspectedactivetuberculosisinalowprevalencearea |